JAK2 and myeloproliferative neoplasm: Despite its general role as a tumor suppressor, a recent study identified a strong synthetic lethal relationship between RECQL5 and an activating V617F mutation in the JAK2 non-receptor tyrosine kinase (24), a common oncogenic lesion in patients with myeloproliferative neoplasms (MPN).